Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

被引：0
|
作者：
U Platzbecker
F Braulke
A Kündgen
K Götze
G Bug
C Schönefeldt
K Shirneshan
C Röllig
M Bornhäuser
R Naumann
J Neesen
A Giagounidis
W-K Hofmann
G Ehninger
U Germing
D Haase
M Wermke
机构：
[1] Medical Clinic and Polyclinic I,Department of Hematology and Oncology
[2] University Hospital,Department of Hematology and Oncology
[3] Technical University Dresden,undefined
[4] University Hospital,undefined
[5] University Göttingen,undefined
[6] University Hospital,undefined
[7] Heinrich Heine University Düsseldorf,undefined
[8] Medical Clinic,undefined
[9] University Hospital,undefined
[10] Technical University Munich,undefined
[11] Clinic of Hematology and Oncology,undefined
[12] J.W. Goethe University Hospital,undefined
[13] Stiftungsklinikum Mittelrhein,undefined
[14] Institute of Medical Genetics,undefined
[15] Medical University Vienna,undefined
[16] St Johannes Hospital,undefined
[17] Clinic of Hematology and Oncology,undefined
[18] Hospital of the Ruprecht Karls University,undefined
来源：
Leukemia | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1403 / 1407
页数：4
相关论文
共 50 条
  • [21] A phase 1b study of glasdegib plus azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Schuster, Michael
    Joris, Magalie
    Krauter, Juergen
    Maertens, Johan
    Breems, Dimitri
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ching, Keith
    O'Brien, Thomas
    Stampino, Corrado Gallo
    Ma, Weidong Wendy
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1689 - 1701
  • [22] Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Tiu, Ramon V.
    Advani, Anjali S.
    Afable, Manual
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Paquette, Ronald
    Smith, April
    Strozniak, Lori
    List, Alan F.
    Maciejewski, Jaroslaw P.
    BLOOD, 2011, 118 (21) : 279 - 279
  • [23] Azacitidine A Review of its Use in Higher-Risk Myelodysplastic Syndromes/Acute Myeloid Leukaemia
    Keating, Gillian M.
    DRUGS, 2009, 69 (17) : 2501 - 2518
  • [24] Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies
    Ades, Lionel
    Prebet, Thomas
    Stamatoullas, Aspasia
    Recher, Christian
    Guieze, Romain
    Raffoux, Emmanuel
    Bouabdallah, Krimo
    Hunault, Mathilde
    Wattel, Eric
    Stalnikiewicz, Laure
    Toma, Andrea
    Dombret, Herve
    Vey, Norbert
    Sebert, Marie
    Gardin, Claude
    Chaffaut, Cendrine
    Chevret, Sylvie
    Fenaux, Pierre
    HAEMATOLOGICA, 2017, 102 (04) : 728 - 735
  • [25] Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
    A Pellagatti
    M Fernandez-Mercado
    C Di Genua
    M J Larrayoz
    S Killick
    H Dolatshad
    A Burns
    M J Calasanz
    A Schuh
    J Boultwood
    Leukemia, 2014, 28 : 1148 - 1151
  • [26] MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES
    Martinez-Hoyer, Sergio
    Deng, Yu
    Parker, Jeremy
    Jiang, Jihong
    Docking, Roderick
    Mo, Angela
    Gharaee, Nadia
    Jadersten, Martin
    Kulasekararaj, Austin
    Malcovati, Luca
    List, Alan
    Hellstrom-Lindberg, Eva
    Platzbecker, Uwe
    Karsan, Aly
    EXPERIMENTAL HEMATOLOGY, 2020, 88 : S72 - S72
  • [27] Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
    Pellagatti, A.
    Fernandez-Mercado, M.
    Di Genua, C.
    Larrayoz, M. J.
    Killick, S.
    Dolatshad, H.
    Burns, A.
    Calasanz, M. J.
    Schuh, A.
    Boultwood, J.
    LEUKEMIA, 2014, 28 (05) : 1148 - 1151
  • [28] FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE
    Madry, K.
    Lis, K.
    Zurawska, J.
    Gorka, M.
    Kacprzyk, P.
    Dutka, M.
    Rodzaj, M.
    Bolkun, L.
    Krochmalczyk, D.
    Drozd-Sokolowska, J.
    Waszczuk-Gajda, A.
    Knopinska-Posluszny, W.
    Kopinska, A.
    Subocz, E.
    Masternak, A.
    Guzicka-Kazimierczak, R.
    Gil, L.
    Machowicz, R.
    Dwilewicz-Trojaczek, J.
    HAEMATOLOGICA, 2017, 102 : 490 - 490
  • [29] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
  • [30] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
12345